Novo Nordisk stock gains outlook support from Wegovy pill demand

Novo Nordisk raised its 2026 outlook on Wednesday, November 4, after third-quarter results showed stronger GLP-1 volume growth, particularly in obesity treatments. The Danish drugmaker now expects adjusted sales and adjusted operating profit to range from a 2 percent decline to 2 percent growth at constant exchange rates, compared with its previous range of a 6 percent decline to zero growth.

Reuters reported that the upgraded outlook was Novo Nordisk's third increase this year. Management cited higher volumes in the United States and international markets, although the outlook assumes international sales growth and declining US sales.

Wegovy pill leads the recovery effort

Wegovy pill sales reached DKK 5.39 billion in the third quarter, up 53 percent from the second quarter and above the DKK 4.62 billion analyst consensus cited by Reuters. The pill had been launched in eight markets by the time of the report, with the company accelerating its rollout and targeting availability in more than 20 countries by mid-2027.

Third-quarter adjusted sales reached DKK 79.20 billion, while adjusted operating profit rose 27 percent at constant exchange rates to DKK 31.72 billion. The comparison benefited from DKK 9 billion of company-wide transformation costs recognized in the third quarter of 2025, so the underlying improvement should not be read as a pure measure of recurring operating momentum.

What changed since the last report

The latest company update adds a higher full-year outlook and a stronger quarterly sales contribution from the oral Wegovy treatment. The stock also moved beyond the automatic second-edition threshold: Novo Nordisk stock traded at 36.23 euros on Lang & Schwarz at 17:06 CET on Thursday, November 5. That compares with 35.76 euros in the October 31 report, a 1.31 percent increase.

Investors still face a mixed setup. The pill is supporting the obesity franchise, but Reuters reported that US injectable Wegovy sales declined at constant exchange rates and that the competitive environment is intensifying. Pricing, US demand and the pace of international launches remain central to the next outlook update.

For a direct market view, see the real-time quote of Novo Nordisk stock.

European equities provide the broader market backdrop; see Current market reports.

More developments are available in more news and analyses on Novo Nordisk stock.